Case report: complete remission with crizotinib in ROS1 fusion-positive sinonasal mucosal melanoma
Frontiers in Oncology(2022)
摘要
IntroductionSinonasal mucosal melanoma (SNMM) originates from melanocytes. Currently, the main treatment methods, including surgery, radiotherapy and chemotherapy, have little effect on the recurrence and metastasis of SNMM. However, targeted therapy may be a breakthrough in treating SNMM. MethodsA SNMM patient with ROS1 fusion received 250mg Crizotinib capsule (2 times a day, 1 tablet each time) therapy. ResultsThe patient achieved partial remission after 4 months of treatment and complete remission after 8 months of treatment. ConclusionOur findings suggest that crizotinib can be an option to improve overall survival and quality of life of patients with metastatic ROS1-fusion SNMM. We believe that our report will provide insights for the application of crizotini in the treatment of melanoma.
更多查看译文
关键词
crizotinib,ROS1,sinonasal,mucosal melanoma,complete remission
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要